Innovent begins phase 3 GLORY-OSA trial for mazdutide in China
June 16, 2025 | 10:00
The clinical trial underscores Innovent’s ambition to deliver innovative obesity treatment to patients across Asia.
Innovent updates IBI363 data in advanced lung cancer at ASCO
June 04, 2025 | 08:00
New Phase 1 results underscore promise of the first-in-class bispecific antibody.
Innovent presents updated IBI363 data in colorectal cancer at ASCO 2025
June 02, 2025 | 16:26
New phase 1 findings highlight promise of first-in-class bispecific antibody fusion for advanced colorectal cancer.
Innovent to Present Promising Phase 2 Data for Breakthrough Eye Drug IBI302 at ARVO 2025
May 06, 2025 | 08:00
A potential game changer in the treatment of retinal disease, the novel dual-target drug shows encouraging results.
Innovent Showcases Breakthrough Preclinical Data on Novel Antibodies at AACR 2025
April 28, 2025 | 08:00
Cutting-edge bispecific and tri-specific antibody therapies headline Innovent’s research portfolio.
Mobile Version